273 related articles for article (PubMed ID: 23636648)
21. Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant.
Beaven AW; Shea TC
Drugs Today (Barc); 2007 Jul; 43(7):461-73. PubMed ID: 17728847
[TBL] [Abstract][Full Text] [Related]
22. Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients.
Arena C; Troiano G; De Lillo A; Testa NF; Lo Muzio L
Biomed Res Int; 2018; 2018():5035217. PubMed ID: 29992147
[TBL] [Abstract][Full Text] [Related]
23. The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue.
Carlotto A; Hogsett VL; Maiorini EM; Razulis JG; Sonis ST
Pharmacoeconomics; 2013 Sep; 31(9):753-66. PubMed ID: 23963867
[TBL] [Abstract][Full Text] [Related]
24. The effect of a supersaturated calcium phosphate mouth rinse on the development of oral mucositis in head and neck cancer patients treated with (chemo)radiation: a single-center, randomized, prospective study of a calcium phosphate mouth rinse + standard of care versus standard of care.
Lambrecht M; Mercier C; Geussens Y; Nuyts S
Support Care Cancer; 2013 Oct; 21(10):2663-70. PubMed ID: 23686379
[TBL] [Abstract][Full Text] [Related]
25. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.
Lo Muzio L; Arena C; Troiano G; Villa A
Oral Dis; 2018 Mar; 24(1-2):144-171. PubMed ID: 29480626
[TBL] [Abstract][Full Text] [Related]
26. Diarrhea With HER2-Targeted Agents in Cancer Patients: A Systematic Review and Meta-Analysis.
Li J
J Clin Pharmacol; 2019 Jul; 59(7):935-946. PubMed ID: 30707455
[TBL] [Abstract][Full Text] [Related]
27. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2014 Jun; 14(6):751-60. PubMed ID: 24666215
[TBL] [Abstract][Full Text] [Related]
28. Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer.
Yokota T; Onoe T; Ogawa H; Hamauchi S; Iida Y; Kamijo T; Suda T; Yurikusa T; Nishimura T; Yasui H; Onitsuka T
Jpn J Clin Oncol; 2015 Feb; 45(2):183-8. PubMed ID: 25420692
[TBL] [Abstract][Full Text] [Related]
29. Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice.
Peterson DE; O'Shaughnessy JA; Rugo HS; Elad S; Schubert MM; Viet CT; Campbell-Baird C; Hronek J; Seery V; Divers J; Glaspy J; Schmidt BL; Meiller TF
Cancer Med; 2016 Aug; 5(8):1897-907. PubMed ID: 27334013
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.
Yu YF; Wang Y; Fu TP; Chen K; Liu JQ; Yao HR
Breast Cancer Res Treat; 2018 Apr; 168(2):337-348. PubMed ID: 29188398
[TBL] [Abstract][Full Text] [Related]
31. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
33. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.
Vigarios E; Epstein JB; Sibaud V
Support Care Cancer; 2017 May; 25(5):1713-1739. PubMed ID: 28224235
[TBL] [Abstract][Full Text] [Related]
34. [Management of chemotherapy-induced mucositis and diarrhea].
Kandabashi K; Sasaki T
Gan To Kagaku Ryoho; 2006 Jan; 33(1):24-8. PubMed ID: 16410693
[TBL] [Abstract][Full Text] [Related]
35. Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy.
Limaye SA; Haddad RI; Cilli F; Sonis ST; Colevas AD; Brennan MT; Hu KS; Murphy BA
Cancer; 2013 Dec; 119(24):4268-76. PubMed ID: 24114811
[TBL] [Abstract][Full Text] [Related]
36. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis.
Abdel-Rahman O; ElHalawani H
Expert Opin Drug Saf; 2015 Oct; 14(10):1495-506. PubMed ID: 26313327
[TBL] [Abstract][Full Text] [Related]
37. Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs.
Mantovani G; Massa E; Astara G; Murgia V; Gramignano G; Lusso MR; Camboni P; Ferreli L; Mocci M; Perboni S; Mura L; Madeddu C; Macciò A
Oncol Rep; 2003; 10(1):197-206. PubMed ID: 12469169
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Pan G; Ke S; Zhao J
Target Oncol; 2013 Jun; 8(2):107-16. PubMed ID: 23516098
[TBL] [Abstract][Full Text] [Related]
39. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
40. Chlorhexidine prophylaxis for chemotherapy- and radiotherapy-induced stomatitis: a randomized double-blind trial.
Ferretti GA; Raybould TP; Brown AT; Macdonald JS; Greenwood M; Maruyama Y; Geil J; Lillich TT; Ash RC
Oral Surg Oral Med Oral Pathol; 1990 Mar; 69(3):331-8. PubMed ID: 2179802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
